EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanomotion technology: an innovative method to study cell metabolism in Escherichia coli, as a potential indicator for tolerance

Christèle Aubry, Carole Kebbi-Beghdadi, Amanda Luraschi-Eggemann, Gino Cathomen, Danuta Cichocka, Alexander Sturm, Gilbert Greub, The Eradiamr Consortium

Journal of Medical Microbiology · 2024

DOI: 10.1099/jmm.0.001912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2024. Verfasst von Christèle Aubry und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Microbiology, Lausanne University Hospital and Lausanne University, CH-1011 Lausanne, Switzerland. Hauptthemen laut MEDLINE: Escherichia coli, Anti-Bacterial Agents, Microbial Sensitivity Tests. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innosuisse - Schweizerische Agentur für Innovationsförderung, ERADIAMR - JPIAMR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Antibiotic tolerance corresponds to the bacterial ability to survive a transient exposure to antibiotics and is often associated with treatment failure. Current methods of identifying tolerance based on bacterial growth are time-consuming. This study explores the use of a growth-independent method utilizing nanomotion technology to detect antibiotic-tolerant bacteria. Hypothesis. The nanomotion signal obtained from a nanomechanical sensor measures real-time metabolic activity and cellular processes and could provide valuable information about the tolerance of bacteria to antibiotics that cannot be detected by standard antibiotic susceptibility tests.

Aim

The aim of this study is to investigate the potential of nanomotion technology to record antibiotic-tolerant bacteria. Methodology. We generated a slow-growing Escherichia coli strain by manipulating mazF expression levels and confirmed its viability by several standard methods. We subsequently measured its nanomotion and the nanomotion of the WT E. coli in the presence or absence of antibiotics. Supervised machine learning was employed to distinguish slow-growing from exponentially growing bacteria. Observations for bacterial nanomotions were confirmed by standard kill curves.

Results

We distinguished slow-growing from exponentially growing bacteria using specific features from the nanomotion signal. Furthermore, the exposition of both growth phenotypes to polymyxin decreased the nanomotion signal indicating cell death. Similarly, when exponentially growing cells were exposed to ampicillin, an antibiotic whose efficacy depends on the growth rate, the nanomotion signal also decreased. In contrast, the nanomotion signal remained unchanged for slow-growing bacteria upon exposure to ampicillin. In addition, antibiotic exposure can cause bacterial elongation, in which the biomass of a cell increases without cell division. By overexpressing sulA , we mimicked antibiotic-induced elongation. Differences in the nanomotion signal were observed when comparing elongating and non-elongating phenotypes.

Conclusion

This work shows that nanomotion signals entail information about the reaction to antibiotics that standard MIC-based antibiotic susceptibility tests cannot detect. In the future, nanomotion-based antibiotic tolerance tests could be developed for clinical use in chronic or relapsing infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliAnti-Bacterial AgentsMicrobial Sensitivity TestsEscherichia coli ProteinsDrug Resistance, BacterialNanotechnologyDNA-Binding ProteinsEndoribonucleases

Stichwörter der Autor:innen

antibioticgrowth-independent methodnanomotionrapid ASTtolerance

Substanzen

Anti-Bacterial AgentsEscherichia coli ProteinsMazF protein, E coliDNA-Binding ProteinsEndoribonucleases

Autor:innen und Institutionen

  • Institute of Microbiology, Lausanne University Hospital and Lausanne University, CH-1011 Lausanne, Switzerland.
  • Resistell AG, Hofackerstrasse 40, CH-4132 Muttenz, Switzerland.

Förderung

  • Innosuisse - Schweizerische Agentur für Innovationsförderung
  • ERADIAMR - JPIAMR

Zitieren

APA

Aubry, C., Kebbi-Beghdadi, C., Luraschi-Eggemann, A., Cathomen, G., Cichocka, D., Sturm, A., Greub, G., & The Eradiamr Consortium (2024). Nanomotion technology: an innovative method to study cell metabolism in Escherichia coli, as a potential indicator for tolerance. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001912

Vancouver

Aubry C, Kebbi-Beghdadi C, Luraschi-Eggemann A, Cathomen G, Cichocka D, Sturm A, et al. Nanomotion technology: an innovative method to study cell metabolism in Escherichia coli, as a potential indicator for tolerance. Journal of Medical Microbiology. 2024. doi:10.1099/jmm.0.001912

BibTeX
@article{Aubry2024,
  author = {Aubry, Christèle and Kebbi-Beghdadi, Carole and Luraschi-Eggemann, Amanda and Cathomen, Gino and Cichocka, Danuta and Sturm, Alexander and Greub, Gilbert and The Eradiamr Consortium},
  title = {Nanomotion technology: an innovative method to study cell metabolism in Escherichia coli, as a potential indicator for tolerance},
  journal = {Journal of Medical Microbiology},
  year = {2024},
  doi = {10.1099/jmm.0.001912}
}
Kostenlos starten →